'Tamper-evident' benefits are evident28 Feb 2019
2019 will mark Uniplast's debut at this year's edition of CPhI Worlwide in Frankfurt, where it will showcase its expertise in plastic packaging.
Pharmaceutical packaging serves numerous purposes and comes in a variety of materials and designs, depending on the drug product.
Uniplast - a regional leader in the manufacture and distribution of pharmaceutical, medical and cosmetic packaging - has used its 27 years of operational expertise and knowhow to develop more than 150 different high-quality products.
Tamper-proof bottles that save time and reduce contamination
The company is renowned for its variety of plastic packaging, particularly its bottles with a tamper-proof cap and integrated dropper, which reduces the packaging process from three to two steps, thereby saving time in product filling and packing, and reduces the risk of contamination while handling the sterile products. These plastic bottles are used for storing liquid pharmaceutical products (magistral medicine, galenical medicine, ready-made medicines, and pharmaceutical substance) and can be in direct contact with the product. Customers can choose the colour of the container
Compliance and certification
Demonstrating its compliance with various regulatory standards, Uniplast's plastic containers and closures are manufactured in accordance with the following: ISO 9001, ISO 14001, OHSAS 18001 and ISO 15378. In 2017, Uniplast implemented ISO 13485, regarding the production, development and sale of sterile and nonsterile IVDs, urine cups, Petri dishes, and swab and faeces containers.
The Uniplast team's creative environment motivates and inspires all those that are in touch with their products and services. Uniplast customers can expect a relationship based on 100% trust and fair co-operation to ensure superior quality products that will improve their sales and facilitate the way to success.
All Recipharm facilities ready for EU serialisation, regardless of Brexit
15 Feb 2019
The CDMO invested EUR 35 million into its operations and launched a 3-year programme to provide a compliant serialisation solution for its customers.Read more
Brexit - the EU FMD's painful problem
7 Feb 2019
Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.Read more
Pharmapack report predicts diversification of innovation leading to a rise in licensing and partnering
27 Jan 2019
New report highlights Germany, France and Switzerland as tier-one nations for ‘drug delivery innovation’, and warns the challenge will be to scale-up and approve promising prototypes.Read more
New API screening program strengthens Particle Sciences' nanomilling offering
22 Jan 2019
Advanced formulation techniques such as nanomilling may provide an excellent route to improved bioavailability and enhanced therapeutic effect.Read more
Univercells introduces breakthrough vaccine manufacturing platform
13 Jan 2019
The automated NevoLine bioproduction system that facilitates safer, faster and closed bioprocessing in a much smaller footprint.Read more
BMS and Celgene merge to create premier innovative biopharma company
3 Jan 2019
Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.Read more
An increased risk of a hard or ‘no deal Brexit?
24 Dec 2018
A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.Read more
One month on: medical cannabis is still taboo despite change in law
11 Dec 2018
Restrictive guidelines have led many to buy CBD products online, leading to a boom in production with many products going to market without sufficient quality control.Read more
EU FMD - time is running out!
13 Nov 2018
Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.Read more
Proprietary nasal delivery formulation of diazepam reaches NDA
7 Nov 2018
The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation